| Literature DB >> 19921150 |
Saskia Nijssen1, Ad Fluit, David van de Vijver, Janetta Top, Rob Willems, Marc J M Bonten.
Abstract
BACKGROUND: We determined the effects of two antibiotic policies (predominance of either beta-lactam antibiotics or fluroquinolones) on acquisition with third-generation cephalosporin-resistant Enterobacteriaceae (CRE) and fluoroquinolone-resistant CRE (FCRE) in two ICUs, with monitoring of other variables that may influence acquisition.Entities:
Mesh:
Substances:
Year: 2010 PMID: 19921150 PMCID: PMC2820219 DOI: 10.1007/s00134-009-1714-y
Source DB: PubMed Journal: Intensive Care Med ISSN: 0342-4642 Impact factor: 17.440
Population characteristics
| Variable | Baseline | Heterogeneous | Homogeneous |
|---|---|---|---|
| Patient demographics | |||
| Patient days | 3,818 | 1,281 | 1,176 |
| Admitted patients | 457 | 176 | 135 |
| Age (years) | 53 ± 19 | 57 ± 18 | 56 ± 15 |
| APACHE II score | 21 ± 8 | 23 ± 8 | 21 ± 7 |
| MICU stay (days) | 8 ± 11 | 7 ± 9 | 9 ± 10 |
| Male sex [no. (%) of patients] | 244 (53.4) | 104 (59.1) | 82 (60.7) |
| Mortality [no. (%)] | 83 (18.2) | 23 (13.6) | 29 (21.5) |
| Admission indication | |||
| Cardiovascular | 30 (6.6) | 9 (5.1) | 9 (6.7) |
| Pulmonary | 94 (20.6) | 36 (20.5) | 34 (25.2) |
| Gastro-intestinal | 10 (2.2) | 4 (2.3) | 0 |
| Neurological | 72 (15.8) | 28 (15.9) | 21 (15.6) |
| Sepsis | 26 (5.7) | 6 (3.4) | 7 (5.2) |
| Trauma | 45 (9.8) | 14 (8.0) | 5 (3.7) |
| Surgery | 139 (30.4) | 72 (40.9) | 49 (36.3) |
| Other | 41 (9.0) | 7 (4.0) | 10 (7.4) |
Colonization characteristics
| Variable | Period |
| ||
|---|---|---|---|---|
| Baseline | Heterogeneous | Homogeneous | ||
| Cephalosporin-resistant Enterobacteriaceae | ||||
| Patients with CRE colonization (%) | 83a (18.2) | 26 (14.8) | 29 (21.5) | 0.31/0.39 |
| Patients with colonization on admission (%) | 33 (7.2) | 11 (6.3) | 12 (8.9) | 0.65/0.53 |
| Patients with acquired colonization (%) | 44 (9.6) | 14 (8.0) | 16 (11.9) | 0.50/0.45 |
| Acquisition rate/1,000 patient days at risk | 14 | 14 | 18 | 0.95/0.69 |
| Mean days to acquisition | 7 ± 9 | 6 ± 7 | 7 ± 8 | 0.71/0.73 |
| Ciprofloxacin-resistant CRE | ||||
| Patients with ciprofloxacin-resistant CRE | 16 (3.5) | 4 (2.3) | 11 (8.1) | 0.43/0.02 |
| Patients with ciprofloxacin-resistant CRE isolate on admission | 9 (2.0) | 1 (0.6) | 1 (0.8) | 0.30/0.47 |
| Patients with acquired ciprofloxacin-resistant CRE isolate | 6 (1.3) | 3 (1.7) | 8 (6.0) | 0.71/< 0.01 |
| Mean days to acquisition | 7 ± 10 | 7 ± 8 | 7 ± 8 | 0.98/0.47 |
| Acquisition rate ciprofloxacin-resistant isolate/1,000 patient days | 2.1 | 2.5 | 8.3 | 0.50/0.01 |
Origin of colonization (i.e., present on admission or acquired) could not be determined for six patients, because cultures were either taken more than 48 h after admission or patients had been admitted before the start of the study period
aThis includes four patients present in the unit at the time of study onset
* Comparison of baseline versus heterogeneous/homogeneous
Contact rates, compliance and cohorting
| Variable | Period |
| ||
|---|---|---|---|---|
| Baseline | Heterogeneous | Homogeneous | ||
| Observation of patients | ||||
| No. of HCW–patient contacts | 435 | 132 | 186 | |
| Contact rates of patients (contacts/h) | 4.0 ± 1.8 | 2.9 ± 1.3 | 4.3 ± 2.5 | 0.01/0.70 |
| Compliance (%) | 55 | 57 | 53 | 0.77/0.73 |
| Physicians (%) | 59 | 63 | 43 | 0.75/0.28 |
| Nurses (%) | 53 | 55 | 58 | 0.73/0.42 |
| Observation of nurses | ||||
| No. of HCW–patient contacts | 352 | 119 | 148 | |
| Contact rates nurses (contacts/h) | 3.2 ± 1.3 | 2.5 ± 1.0 | 2.8 ± 1.4 | 0.02/0.28 |
| Cohorted contacts (%) | 71 ± 22 | 74 ± 23 | 74 ± 25 | 0.66/0.65 |
* Comparison of baseline versus heterogeneous/homogeneous
Risk factors for CRE acquisition
| Variable | Without CRE | Acquired CRE |
| HR | 95% CI interval |
|
|---|---|---|---|---|---|---|
| ( | ( | |||||
| Demographics | ||||||
| Age | 54 ± 18 | 55 ± 18 | 0.81 | |||
| Male sex | 195 (52%) | 26 (59%) | 0.38 | |||
| APACHE II score | 21 ± 8 | 22 ± 6 | 0.58 | |||
| MICU | 229 (61%) | 23 (52%) | 0.25 | |||
| Contact rate | 4.6 ± 3.1 | 5.5 ± 3.6 | 0.22 | |||
| Hand hygiene | 47% ± 41% | 53% ± 39% | 0.59 | |||
| Admission diagnoses | ||||||
| Pulmonary disease | 66 (18%) | 15 (34%) | 0.01 | 2.10 | 0.88–5.03 | 0.09 |
| Cardiovascular disease | 24 (6%) | 1 (2%) | 0.27 | |||
| Neurological disease | 62 (17%) | 5 (11%) | 0.37 | |||
| Trauma | 30 (8%) | 14 (32%) | <0.01 | 2.71 | 1.11–6.61 | 0.03 |
| Surgery | 124 (32%) | 6 (14%) | 0.01 | 1.50 | 0.52–4.35 | 0.45 |
| Other | 68 (18%) | 3(7%) | 0.06 | 1.45 | 0.18–11.91 | 0.73 |
| Antibiotic therapy | 237 (63%) | 44 (100%) | <0.01 | |||
| Amoxicillin–clavulanic acid | 127 (34%) | 32 (73%) | <0.01 | 1.49 | 0.70–3.14 | 0.30 |
| Ceftriaxone | 57 (15%) | 8 (18%) | 0.61 | |||
| Aminoglycosides | 71 (19%) | 22 (50%) | <0.01 | 0.97 | 0.50–1.90 | 0.93 |
| Quinolones | 28 (8%) | 5 (11%) | 0.37 | |||
Antibiotic use during study periods
| Baseline | Heterogeneous | Homogeneous | |
|---|---|---|---|
|
|
|
| |
| No. of patients receiving antibiotics | 306 (67%) | 107 (61%) | 97 (72%) |
| No. of DDD/1,000 patient days | (%Δ to baseline) | (%Δ to baseline) | |
| Amoxicillin–clavulanic acid | 326 | 131 (−60%)* | 31 (−91%)* |
| Ceftriaxone | 134 | 130 (−3%) | 55 (−59%)* |
| Ceftazidime | 21 | 29 (+38%) | 9 (−57%) |
| Piperacillin-tazobactam | 38 | 9 (−74%) | 10 (−74%) |
| Carbapenems | 52 | 60 (+15%) | 96 (+54%) |
| Other beta-lactam antibioticsa | 283 | 167 (−41%) | 354 (+25%) |
| Total beta-lactam antibiotics | 854 | 526 (−39%) | 555 (−35%) |
| Aminiglycosides | 159 | 142 (−11%) | 91 (−43%)* |
| Quinolones | 150 | 129 (−14%) | 514 (+243%)* |
DDD defined daily dosage
aAmoxicillin, flucloxacillin, piperacillin
* p < 0.05 as compared to baseline